10x Genomics
330 hedge funds and large institutions have $2.66B invested in 10x Genomics in 2026 Q1 according to their latest regulatory filings, with 57 funds opening new positions, 115 increasing their positions, 102 reducing their positions, and 42 closing their positions.
1,364% more call options, than puts
Call options by funds: $23.6M | Put options by funds: $1.61M
133% more funds holding in top 10
Funds holding in top 10: 3 → 7 (+4)
36% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 42
32% more capital invested
Capital invested by funds: $2.02B → $2.66B (+$641M)
13% more repeat investments, than reductions
Existing positions increased: 115 | Existing positions reduced: 102
2% more funds holding
Funds holding: 322 → 330 (+8)
0.27% more ownership
Funds ownership: 106.12% → 106.4% (+0.27%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$116M |
| 2 |
BWLSA
Blue Water Life Science Advisors
Larkspur,
California
|
+$21.8M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$19.8M |
| 4 |
Goldman Sachs
New York
|
+$17.7M |
| 5 |
CC
Casdin Capital
New York
|
+$17.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$23.6M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$19M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$17.5M |
| 4 |
Two Sigma Investments
New York
|
-$15.1M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
-$14.6M |
TXG Hedge Fund Activity: Q1 2026 in Review
330 of the 8,173 institutional investors tracked by Wall St. Rank reported a position in 10x Genomics (TXG) for Q1 2026, worth a combined $2.66B — up 32% from $2.02B a quarter earlier.
Buyers outnumbered sellers: 57 funds opened new TXG positions and 42 closed out — a net gain of 15 holders — while 115 added to existing stakes and 102 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $116M. The largest seller was Wellington Management Group, exiting entirely with an estimated $23.6M sold.
- 330 institutional investors held 10x Genomics (TXG) as of Q1 2026, up from 322 in Q4 2025.
- Funds reported $2.66B of 10x Genomics stock for Q1 2026, up 32% quarter-over-quarter.
- 57 funds opened new 10x Genomics positions in Q1 2026 and 42 closed out, a net change of +15 holders.
- The largest 10x Genomics buyer in Q1 2026 was Fidelity Investments, an estimated $116M added.
- The largest 10x Genomics seller in Q1 2026 was Wellington Management Group, an estimated $23.6M sold.
Based on aggregated 13F filings for Q1 2026.